A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors

Publisher： Karger

E-ISSN： 2296-5262|36|11|657-660

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.11, 2013-10, pp. : 657-660

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies

By  

Oncology, Vol. 90, Iss. 1, 2016-0 ,pp. : 10-20

Karger

Access to resources Recommend Favorite

Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 253-259

Karger

Access to resources Recommend Favorite

A Dose-Escalation Study of Oxaliplatin and Vinorelbine in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 213-218

Karger

Access to resources Recommend Favorite

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 69, Iss. 3, 2005-10 ,pp. : 202-207

Karger

Access to resources Recommend Favorite